McDermott Beats Back Drug Patent Challenge for Depomed

, The Litigation Daily

   | 0 Comments

The ruling, which Depomed said would extend its monopoly on the pain drug Gralise for a decade, is a huge relief for the small pharma company and its investors.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202667386908

Thank you!

This article's comments will be reviewed.